Canadian scientists have established for the first time a new mechanism and role for LDL in the development of type 2 diabetes, beyond its traditional role in the development of cardiovascular disease in humans.
Announced today for World Diabetes Day, the work was carried out by Université de Montréal professor May Faraj, director of the nutrition, lipoproteins and cardiometabolic diseases research unit at the Montreal Clinical Research Institute.
Her study is published today in Scientific Reports.
Faraj's research suggests that targeting subjects with high LDL using interventions that reduce inflammation may reduce the incidence of type 2 diabetes as well as that of cardiovascular disease, thus achieving two important goals in one single approach.
Elevated numbers of particles that carry “bad cholesterol” in the blood (LDL) are known to promote the development of cardiovascular disease. Clinical evidence – first uncovered in Faraj’s laboratory 15 years ago and since confirmed in large epidemiological studies – indicate that elevated numbers of LDL also promote the development of type 2 diabetes in humans.
Until now, however, mechanisms linking LDL to the risk of type 2 diabetes weren't well understood.